DALE MICHAEL D 4

What Happened

• Michael D. Dale, CEO of Axogen, Inc. (AXGN), was granted 98,000 restricted stock units (RSUs) on Feb 26, 2026. The filing reports this as an award/grant (transaction code A) with an acquisition price of $0.00 (derivative grant), so no cash was exchanged at grant.

Key Details

• Transaction date: February 26, 2026; Form 4 filed February 27, 2026 (timely).
• Grant size: 98,000 RSUs; reported acquisition price: $0.00 (derivative award).
• Shares owned after the transaction: not specified in the filing.
• Footnote F1: Each RSU represents a contingent right to receive one share of Axogen common stock.
• Footnote F2: Vesting schedule — 50% of the aggregate RSUs vest on Feb 26, 2028; an additional 25% vests each 12 months thereafter, with full vesting on Feb 26, 2030. Vested shares will be delivered upon each vesting date.
• No 10b5-1 plan, tax withholding, cashless exercise, or late-filing indication was disclosed in this Form 4.

Context

• This was an equity compensation award (RSUs), not an open-market purchase or sale. Such grants are common executive compensation and do not themselves indicate immediate buying or selling of stock. The RSUs convert to ordinary shares only as they vest per the schedule above.